Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
AI use in schools: How districts are making sure it's used as a study aid
Recommended
The sun now sets before 8 p.m. Will we ever do away with the time change?
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eisai Ltd ADR
(OP:
ESALY
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EST, Jan 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eisai Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
April 21, 2023
Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid...
Via
Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
April 10, 2023
Via
Benzinga
Tesla Manufactured 4,000 Model Ys In One Week, UBS Prepping For Massive Layoffs, McDonald's Temporary Shuttering Of US Offices: Today's Top Stories
April 03, 2023
Bloomberg UBS Prepping For Massive Layoffs Amid Credit Suisse Takeover
Via
Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
April 03, 2023
The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer...
Via
Benzinga
Daily Stock Analysis: Eisai
March 13, 2023
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's activities consist of a pharmaceutical business and other businesses.
Via
Talk Markets
Lecanemab Receives Priority Review Status in Japan
January 29, 2023
From
Eisai
Via
JCN Newswire
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
January 09, 2023
From
Eisai
Via
JCN Newswire
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
January 09, 2023
From
Eisai
Via
JCN Newswire
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
March 31, 2023
Via
Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
March 21, 2023
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.
Via
InvestorPlace
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
Via
Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
Via
Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
March 06, 2023
Via
Benzinga
1 Green Flag and 1 Red Flag for Biogen
December 23, 2022
Biogen beat the bear market this year.
Via
The Motley Fool
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
December 22, 2022
From
Eisai
Via
JCN Newswire
Why Anavex Life Sciences Stock Bolted Higher in January
February 08, 2023
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.
Via
The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
January 25, 2023
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.
Via
The Motley Fool
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
January 20, 2023
The company will need to complete its confirmatory study before asking for approval.
Via
Investor's Business Daily
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
January 19, 2023
The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.
Via
The Motley Fool
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
January 17, 2023
The fountain of youth might not be a myth in the future.
Via
The Motley Fool
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
January 10, 2023
There's more to the story with Biogen after receiving good news for Leqembi.
Via
The Motley Fool
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill
January 07, 2023
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.
Via
Benzinga
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
January 06, 2023
Via
Benzinga
Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?
January 06, 2023
Biogen is in focus today with the company's lecanemab drug set for an FDA decision on approval, leading to bullish bets on BIIB stock.
Via
InvestorPlace
Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite?
January 06, 2023
CMS already snubbed Biogen's first Alzheimer's drug. Will the second fare better?
Via
Investor's Business Daily
1 Stock Defying the Downturn to Buy, and 1 to Avoid
January 06, 2023
These two stocks might go in different directions in the future.
Via
The Motley Fool
Top Picks For 2023: Catalyst Pharmaceuticals
January 02, 2023
Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...
Via
Talk Markets
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
December 22, 2022
A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.